Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/2/2026 | $6.00 | Buy → Hold | Stifel |
| 3/2/2026 | $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/2/2026 | $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/2/2026 | Buy → Neutral | H.C. Wainwright | |
| 1/28/2026 | $32.00 | Buy | B. Riley Securities |
| 12/23/2025 | $35.00 | Outperform | Oppenheimer |
| 12/12/2025 | Outperform | William Blair | |
| 12/3/2025 | $47.00 | Strong Buy | Raymond James |
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
4 - Aardvark Therapeutics, Inc. (0001774857) (Issuer)
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced it is voluntarily pausing the Phase 3 Hunger Elimination or Reduction Objective (HERO) trial. The HERO trial is a Phase 3 randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of ARD-101 as a treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). The decision by Aardvark to voluntarily pause the HERO (NCT06828861) and open-label extension (NCT0719703
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that (i) on February 9, 2026, five new employees were granted inducement awards consisting of stock options to purchase an aggregate of 147,213 shares of common stock and (ii) on February 11, 2026, one new employee was granted an inducement award consisting of a stock option to purchase 5,125 shares of common stock. Each option was granted pursuant to the Aardvark Therapeutics, Inc. 2025 Induceme
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun's role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. "These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the tr
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
8-K - Aardvark Therapeutics, Inc. (0001774857) (Filer)
Stifel downgraded Aardvark Therapeutics from Buy to Hold and set a new price target of $6.00
Morgan Stanley downgraded Aardvark Therapeutics from Overweight to Equal-Weight and set a new price target of $7.00
RBC Capital Mkts downgraded Aardvark Therapeutics from Outperform to Sector Perform and set a new price target of $6.00
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced the appointment of Derrick C. Li as Chief Business Officer, as well as the expansion of Nelson Sun's role to include Chief Operating Officer, in addition to his current role as Chief Financial Officer. The appointments are effective as of February 9, 2026. "These key appointments for Derrick and Nelson come at a pivotal time for Aardvark as we progress ARD-101 through Phase 3 development for the tr
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (NASDAQ:AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that members of its team will join the Prader-Willi syndrome (PWS) community at the 2025 United in Hope Conference, taking place June 24 to 28 in Phoenix, Arizona. "It's an honor to stand alongside the families, advocates, scientists and clinicians who are working to transform the lives of those affected by PWS," said Dr. Tien Lee, Chief Executive Officer of Aardvark Therapeutics. "The United in